About bosutinib
Tyrosine kinase inhibitor
Used for
- Treats chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia in adults, newly diagnosed or previously treated.
Usual adult dose
Usually 400 mg once daily with food when newly diagnosed; 500 mg once daily with food after prior treatment. Dose may be adjusted.
Common side effects
- Diarrhea, nausea, vomiting, or abdominal pain
- Low blood-cell counts
- Liver enzyme increases
- Rash, fatigue, or headache
Important warnings
- Can cause serious diarrhea, liver injury, low blood counts, or fluid retention.
- Tell the prescriber about liver disease, kidney disease, or heart problems.
- Avoid grapefruit and grapefruit juice; take with food.
- Regular blood tests are needed; dose changes may be required.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment and for at least 2 weeks after the last dose.
Breastfeeding
Do not breastfeed during treatment and for at least 2 weeks after the last dose.
Interactions
- Strong CYP3A inhibitors, such as clarithromycin, can raise bosutinib levels.
- Strong CYP3A inducers, such as rifampin or St. John’s wort, can lower levels.
- Acid-reducing medicines can reduce absorption; separate antacids or H2 blockers, and avoid proton-pump inhibitors.
- May increase levels of medicines transported by P-glycoprotein, including digoxin.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.